Regulation of the concentration of adenosine 3',5'-cyclic monophosphate and the activity of tyrosine hydroxylase in the rat superior cervical ganglion by three neuropeptides of the secretin family.
Preganglionic nerve stimulation leads to an acute elevation of tyrosine hydroxylase (TH) activity in the rat superior cervical ganglion. This effect is mediated in part by acetylcholine, acting via nicotinic receptors, and in part by a noncholinergic neurotransmitter. As a first step in an attempt to identify this noncholinergic transmitter, we have examined a number of biogenic amines, purine nucleotides, neuropeptides, and other compounds for their ability to increase TH activity. Secretin, vasoactive intestinal peptide (VIP), and PHI (a 27-amino acid peptide with an NH2-terminal histidine and a COOH-terminal isoleucine amide), all members of the secretin family of peptides, increased TH activity acutely. Human pancreatic growth hormone-releasing factor, glucagon, and gastric inhibitory peptide (three other members of this peptide family) and all other transmitter candidates tested had no effect on this enzyme activity. We have examined the possibility that this peptidergic regulation of TH activity is mediated via changes in adenosine 3',5'-cyclic monophosphate (cAMP) levels. When the six members of the secretin family were tested for their ability to increase cAMP levels in the ganglion, secretin, VIP, and PHI significantly increased this cyclic nucleotide, whereas growth hormone-releasing factor, glucagon, and gastric inhibitory peptide produced no significant effects. The rank orders of potency and of efficacy of secretin, VIP, and PHI in altering TH activity and cAMP levels were identical. Furthermore, a strong correlation was found between the cAMP level and the TH activity in individual ganglia exposed to these peptides. Finally, 8-bromoadenosine 3',5'-cyclic monophosphate and forskolin also increased TH activity.(ABSTRACT TRUNCATED AT 250 WORDS)
Ip
N Y
NY
Baldwin
C
C
Zigmond
R E
RE
D000818:Animals; D001679:Biogenic Amines / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D004298:Dopamine / Q000096:biosynthesis; D005728:Ganglia, Sympathetic / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D009419:Nerve Tissue Proteins / Q000494:pharmacology; D018377:Neurotransmitter Agents / Q000494:pharmacology; D010455:Peptides / Q000494:pharmacology; D011685:Purine Nucleotides / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D012633:Secretin / Q000494:pharmacology; D014446:Tyrosine 3-Monooxygenase / Q000378:metabolism*; D014660:Vasoactive Intestinal Peptide / Q000494:pharmacology
D001679:Biogenic Amines; D009419:Nerve Tissue Proteins; D018377:Neurotransmitter Agents; D010455:Peptides; D011685:Purine Nucleotides; D012633:Secretin; D014660:Vasoactive Intestinal Peptide; D000242:Cyclic AMP; D014446:Tyrosine 3-Monooxygenase; D004298:Dopamine